文献速递消化系统肿瘤

TGFβ信号通路失活在晚期胰腺癌中呈趋同演化

Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer.
PubMed 文献 · Cancer Discov · 2026-01-01

对30例晚期胰腺癌尸检的250份多区域肿瘤组织行全外显子测序,发现TGFβ通路趋同演化常见;SMAD4失活多见于初诊转移性PDAC,而TGFβ表面受体失活多见于局部晚期非转移癌,小鼠原位模型验证了转移倾向差异。

要点

  • 晚期PDAC中TGFβ通路趋同演化常见,SMAD4与TGFβ受体失活对应不同转移表型。
  • SMAD4失活与初诊转移相关,TGFβ受体失活与局部晚期非转移相关。
  • 放疗后PDAC基因组复杂度更高且突变特征不同,但未发现治疗归因的功能性驱动突变。

核心结论

  • TGFβ通路趋同失活是晚期胰腺癌常见特征,SMAD4与TGFβ受体失活分别对应转移与局部晚期表型。

研究设计与样本

  • 对30例晚期胰腺癌研究性尸检的250份多区域肿瘤组织行全外显子测序。
  • 用携带SMAD4或TGFBR2失活的PDAC类器官行小鼠原位注射进行正交验证。

主要发现

  • TGFβ通路趋同演化在晚期疾病中常见。
  • SMAD4失活在初诊转移性PDAC中更常见,TGFβ表面受体失活在局部晚期非转移癌中更常见。
  • 小鼠原位注射验证了SMAD4与TGFBR2失活对应的转移倾向差异。
  • 未发现归因于治疗的功能性有害驱动基因突变。
  • 放疗后PDAC基因组复杂度显著更高且突变特征不同。

临床怎么用

  • SMAD4与TGFβ受体失活模式或可辅助区分局部晚期与转移性PDAC。
  • 上述特征有望作为生物标志物筛选最可能从新辅助放化疗获益的临界可切除或局部晚期PDAC。

局限性

  • 研究基于尸检多区域采样,样本来源与数量有限。
  • 治疗相关分析为观察性比较,未发现治疗归因驱动突变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We performed whole-exome sequencing of 250 unique tumor tissues from 30 multi-region sampled pancreatic cancer research autopsies from patients diagnosed with advanced-stage disease. Convergent evolution within the TGFβ pathway is a common feature of advanced-stage disease. However, SMAD4 inactivation is more common among de novo metastatic pancreatic ductal adenocarcinomas (PDAC), whereas inactivation of TGFβ surface receptors is more common among locally advanced nonmetastatic cancers. These differences in metastatic propensity were orthogonally validated in mice by orthotopic injections of PDAC organoids with SMAD4 versus TGFBR2 inactivation. No functionally deleterious driver gene mutations were identified that were attributed to treatment, although irradiated PDACs had significantly greater genomic complexity and distinct mutational signatures compared with PDACs managed by chemotherapy. These findings provide a high-level profile of the genetic features distinguishing locally advanced from metastatic PDAC, potentially serving as a biomarker of borderline resectable or locally advanced PDACs most likely to benefit from neoadjuvant chemoradiation. SIGNIFICANCE: This study fills an important gap in knowledge related to the characteristics of genomic alterations of advanced-stage disease. We expect that these findings will serve as a baseline reference set to identify mechanisms of resistance as novel therapies continue to become available for patients with PDAC.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Hong J, Kohutek ZA, Zhang H, et al. Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer. Cancer Discov. 2026. PMID: 41650466. doi:10.1158/2159-8290.CD-24-0772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。